TearLab Corp  

(Public, NASDAQ:TEAR)   Watch this stock  
Find more results for TEAR
1.98
+0.11 (5.88%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.85 - 2.03
52 week 1.50 - 5.97
Open 1.90
Vol / Avg. 108,398.00/71,912.00
Mkt cap 66.61M
P/E     -
Div/yield     -
EPS -0.78
Shares 33.66M
Beta 3.30
Inst. own 37%
Aug 5, 2015
Q2 2015 Tearlab Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Tearlab Corp at ROTH Healthcare Day - London
May 7, 2015
Q1 2015 TearLab Corp Earnings Call
May 7, 2015
Q1 2015 Tearlab Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -151.04% -120.31%
Operating margin -149.24% -126.81%
EBITD margin - -111.91%
Return on average assets -95.42% -58.58%
Return on average equity -157.13% -72.16%
Employees 132 -
CDP Score - -

Address

Suite 200, 7360 Carroll Rd
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company's wholly owned subsidiary TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable, the TearLab Pen and the TearLab Reader.

Officers and directors

Elias Vamvakas Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph Jensen President, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
William G. Dumencu Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Raymond Kong Vice President - Sales
Bio & Compensation  - Reuters
Venkiteshwar Manoj Vice President of Medical Affairs
Age: 37
Bio & Compensation  - Reuters
Paul Smith Vice President - International Markets
Age: 37
Bio & Compensation  - Reuters
Duane Morrison Vice President - Business Development
Age: 51
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas N. Davidson Jr. Independent Director
Age: 55
Bio & Compensation  - Reuters
Adrienne L. Graves Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters